Syros Pharmaceuticals’ (SYRS) “Hold” Rating Reaffirmed at Brookline Capital Management

Brookline Capital Management reiterated their hold rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Wednesday morning,Benzinga reports.

Several other equities research analysts have also weighed in on the company. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. StockNews.com lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday. Finally, Piper Sandler restated an “overweight” rating and issued a $5.00 price target (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Syros Pharmaceuticals has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $0.36 on Wednesday. Syros Pharmaceuticals has a 52 week low of $0.35 and a 52 week high of $8.17. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The company’s 50-day moving average price is $2.07 and its two-hundred day moving average price is $3.84. The stock has a market cap of $9.63 million, a PE ratio of -0.12 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the prior year, the company earned ($1.35) earnings per share. As a group, sell-side analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other Syros Pharmaceuticals news, CFO Jason Haas bought 35,363 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were bought at an average price of $1.55 per share, for a total transaction of $54,812.65. Following the acquisition, the chief financial officer now directly owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. This trade represents a 100.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Jason Haas purchased 35,363 shares of the stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $1.55 per share, for a total transaction of $54,812.65. Following the acquisition, the chief financial officer now directly owns 59,915 shares in the company, valued at approximately $92,868.25. The trade was a 100.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Conley Chee acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average price of $1.51 per share, with a total value of $75,500.00. Following the completion of the acquisition, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. This represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 130,707 shares of company stock worth $206,491. 12.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several institutional investors have recently made changes to their positions in SYRS. Kennedy Capital Management LLC acquired a new position in Syros Pharmaceuticals in the first quarter worth approximately $2,166,000. Vanguard Group Inc. grew its position in Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals during the 1st quarter worth $64,000. Acadian Asset Management LLC acquired a new position in shares of Syros Pharmaceuticals during the 1st quarter worth $91,000. Finally, Certuity LLC bought a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at $109,000. 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.